Stay updated on TNBC Neoadjuvant and Adjuvant Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the TNBC Neoadjuvant and Adjuvant Pembrolizumab Clinical Trial page.

Latest updates to the TNBC Neoadjuvant and Adjuvant Pembrolizumab Clinical Trial page
- Check3 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.4%
- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check25 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.6%
- Check54 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check68 days agoChange DetectedThe webpage has been updated to include new drug information related to the treatment of triple negative breast cancer, specifically mentioning Doxorubicin, Epirubicin, Cyclophosphamide, and Granulocyte colony stimulating factor. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference14%
- Check75 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 9, 2025.SummaryDifference0.2%
Stay in the know with updates to TNBC Neoadjuvant and Adjuvant Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TNBC Neoadjuvant and Adjuvant Pembrolizumab Clinical Trial page.